Clinical TrialsAstraZeneca's confidence in the upcoming approval of treatments is backed by encouraging interactions with regulatory bodies like the FDA.
Financial PerformanceSales and revenue grew 21% in the quarter, not showing any slowdown, while operating expenses and more particularly SG&A costs increased at a lower pace.
Pipeline And GrowthAnalysts see the potential for pipeline progress to drive increased confidence in AstraZeneca's long-term growth outlook, which could lead to a re-rating of its shares.